The Fundstrat Granny Shots US Large Cap ETF (GRNY) is maintained at a 'hold' rating because of its elevated risk profile and reliance on the AI spending cycle and declining interest rates. GRNY focuses on growth stocks with significant exposure to AI infrastructure, resulting in a high portfolio beta of 1.32, indicating higher volatility. Although its historical growth is similar to the IVV ETF, GRNY expects higher forward earnings growth but trades at a less attractive valuation based on growth-at-a-reasonable-price metrics. The ETF rebalances quarterly, and its fundamentals remain consistent, reflecting a bullish high-growth strategy by Tom Lee that appears firmly in place.
The Fundstrat Granny Shots US Large Cap ETF (GRNY) is noted for its high portfolio beta of 1.32, indicating elevated volatility. For readers following US stocks, here is Pluang's market snapshot as of Oct 19, 2026 19:41 WIB: out of 150 priced US stocks tradable on Pluang, 77 rose and 70 fell today. Notable movers include UMC at USD 20.51 (+3.48%), JBLU at USD 3.03 (+3.41%), and PLUG at USD 1.44 (+2.86%).
Disc Medicine's stock surged 38% following positive Phase 3 trial results for its drug bitopertin, which showed efficacy and safety in treating erythropoietic protoporphyria. BMO Capital raised its price target from $100 to $120 and maintained an Out...
Qualcomm executive Ann C. Chaplin sold 1,827 shares of the company's stock for $319,268.25 under a Rule 10b5-1 trading plan, reducing her holdings by 6.62%. Qualcomm's stock price recently traded below its 50-day and 200-day moving averages, signalin...
BOK Financial is set to announce its Q3 2026 earnings after market close on October 19, with analysts forecasting earnings per share between $2.52 and $2.54 and revenue near $571 million. The company has a strong history of surpassing earnings estima...
AIBotics has completed the acquisition of NovaCore Labs' assets from PlayJamaica Limited, gaining technology, software, drones, mapping equipment, and customer contracts. This move expands AIBotics' platform in Jamaica and the Caribbean, enhancing AI...
EyePoint's stock dropped sharply after its DURAVYU treatment did not meet the primary endpoint in a Phase 3 trial for wet age-related macular degeneration (wet AMD). Although DURAVYU showed some vision improvement and reduced the need for additional ...
